Evidence map›Paper›PMID 35872644›Full record

Trial reportClinical infectious diseases : an official publication of the Infectious Diseases Society of America2023

Timeliness of Point-of-Care Viral Load Results Improves Human Immunodeficiency Virus Monitoring in Nigeria.

Beth Chaplin, Oche Agbaji, Harry Reyes Nieva, Bola Olatunde, Charlotte Chang, Kiren Mitruka, Halima Sule, Titus Dajel, Aaron Zee, Mukhtar L Ahmed and 4 more

Registry-linked trialAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03533868 (Reaching 90% Target of HIV Viral Suppression), which is not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03533868 nacompletednot on this map

Reaching 90% Target of HIV Viral Suppression: The Role of Point-of-Care Viral Load Monitoring in Resource-Constrained Settings in Nigeria

TypeinterventionalSponsorHarvard School of Public Health (HSPH)Ran2018 to 2021Enrolled543ConditionsHIV/AIDSArmsPoint-of-care viral load monitoring test
3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Trial
  2. Clinical Outcomes in a Randomized Controlled Trial Comparing Point-of-Care With Standard Human Immunodeficiency Virus (HIV) Viral Load Monitoring in Nigeria.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023
    Trial
  3. The Critical Importance of Clinical Use Case to Inform Point-of-Care Technology Development: A Case Study of HIV Nucleic Acid Assays in the United States.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Beth ChaplinDepartment of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA.
Oche AgbajiDepartment of Medicine, Jos University Teaching Hospital, Jos, Nigeria.
Harry Reyes NievaDepartment of Biomedical Informatics, Columbia University, New York, New York, USA.
Bola OlatundeDepartment of Medicine, Jos University Teaching Hospital, Jos, Nigeria.
Charlotte ChangDepartment of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA.
Kiren MitrukaDivision of Global HIV and TB, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Halima SuleDepartment of Medicine, Jos University Teaching Hospital, Jos, Nigeria.
Titus DajelDepartment of Medicine, Jos University Teaching Hospital, Jos, Nigeria.
Aaron ZeeDivision of Global HIV and TB, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Mukhtar L AhmedCenters for Disease Control and Prevention, Abuja, Nigeria.
Isah AhmedAPIN Public Health Initiatives, Abuja, Nigeria.
Prosper OkonkwoAPIN Public Health Initiatives, Abuja, Nigeria.
Holly RawizzaDepartment of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA.ORCID 0000-0003-3599-1468
Phyllis KankiDepartment of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA.

Funding

Centers for Disease Control and Prevention (CDC; GH-16-005CGH CDC HHS U01 GH002109
6 · The paper itself

Abstract

backgroundHuman immunodeficiency virus (HIV) viral load (VL) monitoring is critical for antiretroviral therapy (ART) management. Point-of-care (POC) VL testing has been reported to be feasible and preferred over standard-of-care (SOC) testing in many low- and middle-income country settings where rapid results could improve patient outcomes.

methodsThe timeliness of receipt of VL results was evaluated in an open-label, randomized, controlled trial among patients newly initiating ART. Clinical outcomes with POC VL monitoring using Cepheid Xpert vs SOC VL at Jos University Teaching Hospital and Comprehensive Health Centre Zamko in Nigeria were assessed. We determined time between specimen collection and recording of VL in patient charts, receipt of results, and ART switch for those who met virologic failure criteria.

resultsBetween April 2018 and October 2019, we screened 696 ART-naive individuals; 273 were randomized to POC and 268 to SOC HIV-1 VL testing. Participants in the POC arm received VL results significantly faster than those in the SOC arm (0.1 median days, interquartile range [IQR], 0.1-0.2 vs 143.1 days, IQR, 56.0-177.1, respectively; P < .0001). Participants in the POC arm with confirmed virologic failure vs those in the SOC arm were switched more rapidly to a second-line regimen (0 median days, IQR, 0-28 vs 66 days, IQR, 63-123, respectively; P = .03).

conclusionsPOC VL testing resulted in significant improvement in the timeliness of VL result receipt by patients and use for effective HIV clinical management. In patients experiencing VL failure, POC monitoring enabled prompt switching to second-line ART regimens. CLINICAL TRIALS REGISTRATION: NCT03533868.

Indexed as

Anti-HIV AgentsHIV-1HIV InfectionsHumansNigeriaPoint-of-Care SystemsPoint-of-Care TestingViral LoadAnti-HIV AgentsAfricaHIVmonitoringpoint-of-careviral load

Identifiers

PMID35872644
PMCPMC11150521

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.